ANXA2 and ovarian cancer: The results of the scratch test and Transwell assay showed that interference with ANXA2 significantly reduced the migration and invasive ability of ovarian cancer cells (P <0.05; Figure 4D, E, F), and exogenous HE4 active protein supplementation did not significantly restore the migratory and invasive ability after 12 h (P >0.05).